Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 12/20 | 0.67 |
| ▸ | SLC6A3 | Q01959 | 12/20 | 0.67 |
| ▸ | SLC6A2 | P23975 | 11/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27752369 | 0.84 | SLC6A4 (0.64) | SLC6A4SLC6A3SLC6A2CYP2D6GRIN1 | |
| SCHEMBL2943873 | 0.81 | SLC6A4 (1.00) | SLC6A4SLC6A3SLC6A2CYP2D6 | |
| SCHEMBL2951070 | 0.81 | SLC6A4 (1.00) | SLC6A4SLC6A3SLC6A2CYP2D6 | |
| SCHEMBL2948711 | 0.81 | SLC6A4 (1.00) | SLC6A4SLC6A3SLC6A2CYP2D6 | |
| SCHEMBL2946591 | 0.79 | SLC6A4 (0.56) | SLC6A4SLC6A3SLC6A2MAPK14 | |
| SCHEMBL8567524 | 0.75 | SLC6A2 (0.47) | SLC6A4SLC6A3SLC6A2SIGMAR1 | |
| SCHEMBL2946646 | 0.72 | SLC6A4 (0.85) | SLC6A4SLC6A3SLC6A2CYP2D6 | |
| SCHEMBL2941760 | 0.72 | SLC6A4 (0.80) | SLC6A4SLC6A3SLC6A2CYP2D6 | |
| SCHEMBL2953333 | 0.72 | SLC6A4 (0.78) | SLC6A4SLC6A3SLC6A2CYP2D6 | |
| SCHEMBL2950368 | 0.70 | SLC6A4 (0.74) | SLC6A4SLC6A3SLC6A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106573888-A | Multi-component crystals of vismodegib and selected co-crystal formers or solvents | 巴斯夫欧洲公司 | 2017-04-19 | — | — | CN | claimed |
| US-7754721-B2 | Arylpiperazine derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2010-07-13 | — | — | US | claimed |
| US-20080090899-A1 | Application of water and organic solvent soluble ivermectin for topical and oral use | PHARMACEUTICAL SOLUTIONS, INC. (US) | 2008-04-17 | — | — | US | claimed |
| US-20060147481-A1 | Ketoprofen powder for oral use | STROBEL MICHAEL | 2006-07-06 | — | — | US | claimed |
| US-6995190-B2 | Method and treatment with ketoprofen solution | VETERINARY SOLUTIONS (US) | 2006-02-07 | — | — | US | claimed |
| US-20050009762-A1 | Application of water and organic solvent soluble ivermectin for topical and oral use | PHARMACEUTICAL SOLUTION, INC. | 2005-01-13 | — | — | US | claimed |
| US-6627613-B2 | Stable, palatable solution of Ivermectin in water is provided for the mass medication of animals | ASSOCIATED BANK, NATIONAL ASSOCIATION, AS AGENT | 2003-09-30 | — | — | US | claimed |
| US-20030040494-A1 | Application of water and organic solvent soluble invermectin for topical and oral use | ASSOCIATED BANK, NATIONAL ASSOCIATION, AS AGENT | 2003-02-27 | — | — | US | claimed |
| US-20020169212-A1 | Ketoprofen powder for oral use | ASSOCIATED BANK, NATIONAL ASSOCIATION, AS AGENT | 2002-11-14 | — | — | US | claimed |
| JP-59122576-A | — | — | None | — | — | JP | disclosed |
| EP-3177591-A1 | MULTI-COMPONENT CRYSTALS OF VISMODEGIB AND SELECTED CO-CRYSTAL FORMERS OR SOLVENTS | BASF SE (DE) | 2017-06-14 | — | — | EP | disclosed |
| CN-106573888-A | Multi-component crystals of vismodegib and selected co-crystal formers or solvents | 巴斯夫欧洲公司 | 2017-04-19 | — | — | CN | disclosed |
| CN-106373783-A | High-performance working electrolyte solution for capacitor | 安徽飞达电气科技有限公司 | 2017-02-01 | — | — | CN | disclosed |
| WO-2016020324-A1 | MULTI-COMPONENT CRYSTALS OF VISMODEGIB AND SELECTED CO-CRYSTAL FORMERS OR SOLVENTS | BASF SE (DE) | 2016-02-11 | — | — | WO | disclosed |
| EP-0243483-A4 | PYRIDYL-PYRIDAZONE AND PYRIDYL-PYRAZOLINONE CARDIOTONICS | — | 1990-10-10 | — | — | EP | disclosed |
| EP-0108380-B1 | PYRIDO 2,3-D PYRIDIMIN-5-ONES | STERLING DRUG INC. (US) | 1989-02-22 | — | — | EP | disclosed |
| EP-0243483-A1 | PYRIDYL-PYRIDAZONE AND PYRIDYL-PYRAZOLINONE CARDIOTONICS | RORER INTERNATIONAL (OVERSEAS) INC. (a Delaware corporation) (US) | 1987-11-04 | — | — | EP | disclosed |
| WO-1987002587-A1 | PYRIDYL-PYRIDAZONE AND PYRIDYL-PYRAZOLINONE CARDIOTONICS | RORER INTERNATIONAL (OVERSEAS) INC. (US) | 1987-05-07 | — | — | WO | disclosed |
| JP-S59122576-A | THERMOCHROMIC COMPOSITION | SAKURA COLOR PROD CORP | 1984-07-16 | — | — | JP | disclosed |
| EP-0063754-A1 | Pyrazolopyridine derivatives, and preparation, useful as cardiotonics | STERLING DRUG INC. (US) | 1982-11-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009762-A1 | Application of water and organic solvent soluble ivermectin for topical and oral use | AQP1, AQP4, AQP3 | SLC6A4 3074/4885SLC6A3 2243/4885SLC6A2 2682/4885 |
| US-20060147481-A1 | Ketoprofen powder for oral use | PKLR, PHYKPL, KYAT3 | SLC6A4 789/4885SLC6A3 542/4885SLC6A2 1205/4885 |
| US-20020169212-A1 | Ketoprofen powder for oral use | PKLR, PHYKPL, KYAT3 | SLC6A4 789/4885SLC6A3 542/4885SLC6A2 1205/4885 |
| US-20030040494-A1 | Application of water and organic solvent soluble invermectin for topical and oral use | SI, AQP1, MMP1 | SLC6A4 3434/4885SLC6A3 2117/4885SLC6A2 3221/4885 |
| US-20080090899-A1 | Application of water and organic solvent soluble ivermectin for topical and oral use | AQP1, AQP4, AQP3 | SLC6A4 3074/4885SLC6A3 2243/4885SLC6A2 2682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.